These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23534065)

  • 1. Molecularly targeted therapies: mechanisms of resistance. Abstracts of the AACR (American Association for Cancer Research) Special Conference. May 9-12, 2012. San Diego, California, USA.
    Clin Cancer Res; 2012 May; 18(10 Suppl):A1-68, B1-68, IA1-15, PR1-8. PubMed ID: 23534065
    [No Abstract]   [Full Text] [Related]  

  • 2. Abstracts of AACR/SNMMI (American Association for Cancer Research/Society of Nuclear Medicine and Molecular Imaging) State-of-the-Art Molecular Imaging in Cancer Biology and Therapy Conference. February 27-March 2, 2013. San Diego, California, USA.
    J Nucl Med; 2013 Feb; 54 Suppl 1():1-35. PubMed ID: 23405410
    [No Abstract]   [Full Text] [Related]  

  • 3. Abstracts of the AACR (American Association for Cancer Research)-IASLC (International Association for the Study of Lung Cancer) Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine. January 8-11, 2012. San Diego, California, USA.
    Clin Cancer Res; 2012 Feb; 18(3 Suppl):IA1-23, PR1-6, A1-46, B1-46. PubMed ID: 23534066
    [No Abstract]   [Full Text] [Related]  

  • 4. AACR meeting highlights new findings on drug resistance, targeted therapies.
    Printz C
    Cancer; 2013 Sep; 119(18):3259. PubMed ID: 24037707
    [No Abstract]   [Full Text] [Related]  

  • 5. [Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs].
    Noguchi K
    Yakugaku Zasshi; 2017; 137(2):151-160. PubMed ID: 28154324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abstracts of the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. October 22-26, 2007. San Francisco, California, USA.
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 2):3331s-704s. PubMed ID: 18300399
    [No Abstract]   [Full Text] [Related]  

  • 7. Taking advantage of drug resistance, a new approach in the war on cancer.
    Wang L; Bernards R
    Front Med; 2018 Aug; 12(4):490-495. PubMed ID: 30022460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attacking cancer with molecularly targeted agents.
    Santoro M; Carlomagno F
    Curr Opin Pharmacol; 2013 Aug; 13(4):483-5. PubMed ID: 23871444
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug resistance to targeted therapies: déjà vu all over again.
    Groenendijk FH; Bernards R
    Mol Oncol; 2014 Sep; 8(6):1067-83. PubMed ID: 24910388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets and cancer therapeutics. 19th annual AACR-NCI-EORTC conference October 22-26, 2007, San Francisco, California, USA.
    Lukan CD
    Eur J Cancer; 2008 Jan; 44(2):168. PubMed ID: 18335585
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
    Izar B; Rotow J; Gainor J; Clark J; Chabner B
    Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AACR-NCI-EORTC International Conference 2009.
    Awada A; Lacombe D
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):319-20. PubMed ID: 20214512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming cancer resistance.
    Cook KL; Clarke R
    Future Med Chem; 2015 Aug; 7(12):1471. PubMed ID: 26334204
    [No Abstract]   [Full Text] [Related]  

  • 16. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
    Bellail AC; Hao C
    Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
    [No Abstract]   [Full Text] [Related]  

  • 17. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
    Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
    Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology.
    Franks ME; Macpherson GR; Lepper ER; Figg WD; Sparreboom A
    Drug Resist Updat; 2003 Dec; 6(6):301-12. PubMed ID: 14744494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted cancer therapy: some lessons from the past decade.
    Huang M; Shen A; Ding J; Geng M
    Trends Pharmacol Sci; 2014 Jan; 35(1):41-50. PubMed ID: 24361003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer and natural selection.
    Fillon M
    J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.